文章：

抗胸腺细胞球蛋白可改善高侵袭性T细胞肿瘤患者异基因造血干细胞移植的预后

Anti-thymocyte globulin could improve the outcome of allogeneic hematopoietic stem cell transplantation in patients with highly aggressive T-cell tumors

原文发布日期：2015-07-31

DOI: 10.1038/bcj.2015.54

类型: Original Article

开放获取: 是

英文摘要：

The early experiment result in our hospital showed that anti-thymocyte globulin (ATG) inhibited the proliferation of lymphoid tumor cells in the T-cell tumors. We used the ATG as the part of the conditioning regimen and to evaluate the long-term anti-leukemia effect, the safety and complication in the patients with highly aggressive T-cell lymphomas. Twenty-three patients were enrolled into this study. At the time of transplant, six patients reached first or subsequent complete response, three patients had a partial remission and 14 patients had relapsed or primary refractory disease. The conditioning regimen consisted of ATG, total body irradiation, toposide and cyclophosphamide. The complete remission rate after transplant was 95.7%. At a median follow-up time of 25 months, 16 (69.6%) patients are alive and free from diseases, including nine patients in refractory and progressive disease. Seven patients died after transplant, five from relapse and two from treatment-related complications. The incidence of grades II–IV acute graft-vs-host disease (GvHD) was 39.1%. The maximum cumulative incidence of chronic GvHD was 30%. The most frequent and severe conditioning-related toxicities observed in 8 out of 23 patients were grades III/IV infections during cytopenia. Thus, ATG-based conditioning is a feasible and effective alternative for patients with highly aggressive T-cell tumors.

摘要翻译： 

我院早期实验结果显示，抗胸腺细胞球蛋白（ATG）可抑制T细胞肿瘤中淋巴肿瘤细胞的增殖。本研究将ATG作为预处理方案的一部分，旨在评估其对高侵袭性T细胞淋巴瘤患者的长期抗白血病效应、安全性及并发症。共纳入23例患者，移植时6例达到首次或后续完全缓解，3例部分缓解，14例为复发或原发难治性疾病。预处理方案包含ATG、全身照射、依托泊苷和环磷酰胺。移植后完全缓解率达95.7%。中位随访25个月，16例（69.6%）患者无病生存，其中包含9例难治性及疾病进展患者。移植后7例死亡，5例源于复发，2例源于治疗相关并发症。II-IV级急性移植物抗宿主病发生率为39.1%，慢性移植物抗宿主病最大累积发生率为30%。23例患者中有8例出现最常见且严重的预处理相关毒性反应，为血细胞减少期间的III/IV级感染。研究表明，基于ATG的预处理方案是高侵袭性T细胞肿瘤患者可行且有效的治疗选择。

原文链接：

Anti-thymocyte globulin could improve the outcome of allogeneic hematopoietic stem cell transplantation in patients with highly aggressive T-cell tumors